EGFR and lung cancer: Common NSCLC driver genes, such as epidermal growth factor receptor, anaplastic lymphoma kinase, and c-ros oncogene 1-receptor tyrosine kinase, are corresponding molecular targeted drugs, which can significantly prolong the disease control time and OS in patients with lung cancer (13, 14).